To this end, we treated a panel of ABC-DLBCL cell lines (U2932, TMD8, and HBL1) with increasing concentrations of the GPX4 inhibitor ML210, in the presence or absence of rising concentrations of ibrutinib. The gene discussed is GPX4; the disease is diffuse large B-cell lymphoma.